intra-arterial cocktail therapy

PreclinicalSmall molecule

intra-arterial cocktail therapy is one of 27 small molecule programs targeting Ischemic stroke. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Ischemic StrokeActive, not recruiting

Ischemic StrokePreclinical

Active, not recruiting

Competition

Competitive Landscape

430 competitors in Ischemic Stroke

#DrugCompanyPhaseTrials

Repatha

Amgen

Preclinical

2 2

Levaquin

WWim Janssens

Preclinical

3 3

Tylenol

KKenvue Brands

Preclinical

1 4

Solu-Medrol

MMassachusetts Eye and Ear Infirmary

Preclinical

1 5

Xylocaine

CCitius Pharmaceuticals, Inc.

Preclinical

1 6

Statins

Sanofi

Preclinical

1 7

Urokinase

Mmedac GmbH

Preclinical

3 8

Drug Therapy

MMassachusetts General Hospital

Preclinical

1 9

Ginkgo Biloba Extract

NNational Center for Complementary and Integrative Health (NCCIH)

Preclinical

1 10

Aspirin or Clopidogrel

SSunnybrook Health Sciences Centre

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Ischemic stroke4 trials

Improving Neuroprotective Strategy for Ischemic Stroke With Sufficient Recanalization After Thrombectomy by Intra-arterial Cocktail Therapy (INSIST-CT)

Completed·HHui-Sheng Chen·N/A·NCT04202549·30 enrolled

Improving Neuroprotective Strategy for Ischemic Stroke With Poor Recanalization After Thrombectomy by Intra-arterial TNK (INSIST-TNK)

Recruiting·HHui-Sheng Chen·N/A·NCT04201964·30 enrolled

Intra-arterial Neuroprotective Strategy for Ischemic STroke Patients With Endovascular Therapy (INSIST-ET)

Recruiting·HHui-Sheng Chen·N/A·NCT04664933·30 enrolled

Show 1 more trial

Intra-arterial Neuroprotective Strategy for Ischemic STroke Patients With No Reperfusion Therapy (INSIST-NRT)

Recruiting·HHui-Sheng Chen·N/A·NCT04664946·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for intra-arterial cocktail therapy. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — intra-arterial cocktail therapy compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for intra-arterial cocktail therapy. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Hui-Sheng Chen company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: HHui-Sheng Chen

intra-arterial cocktail therapy

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Ischemic stroke4 trials

References

Drug Info

Quick Facts

Related News